Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.
Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.